Diagnostic Accuracy of Howell-Jolly Bodies in HIV-Associated Splenic Dysfunction: A Review.

Article · May 2024

CITATIONS
0

READ
1

1 author:

Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)
1,630 PUBLICATIONS **21,998** CITATIONS

SEE PROFILE

Elite Journal of Laboratory Medicine. Volume 2 issue 5(2024), Pp. 13-23
https://epjournals.com/journals/EJLM

Diagnostic Accuracy of Howell-Jolly Bodies in HIV-Associated Splenic Dysfunction: A Review

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Howell-Jolly bodies (HJBs), observed as cytoplasmic remnants within erythrocytes, have emerged as potential indicators of splenic dysfunction in HIV-infected individuals. This review evaluates the diagnostic accuracy of HJBs in identifying HIV-associated splenic dysfunction, examining their morphological features, clinical significance, and implications for disease management. HJBs exhibit characteristic morphological features, including small, round, basophilic inclusions within erythrocytes, typically visualized on peripheral blood smears. While traditionally associated with functional asplenia or splenic dysfunction, the presence of HJBs in HIV patients suggests underlying abnormalities in erythropoiesis and compromised splenic function. Quantitative assessment of HJB abundance may offer valuable diagnostic insights, guiding risk stratification and prognostication for HIV-infected individuals with splenic dysfunction, thereby informing disease management strategies. Despite their potential as biomarkers of splenic dysfunction, the diagnostic accuracy of HJBs in identifying HIV-associated splenic dysfunction remains uncertain. While the presence of HJBs on peripheral blood smears is suggestive of splenic dysfunction, it lacks specificity to HIV and may be observed in other conditions.

Keywords*: Howell-Jolly bodies, HIV, splenic dysfunction, diagnostic accuracy, hematological abnormalities, disease progression*

Introduction

HIV infection continues to be a global public health concern, with an estimated 38 million people living with the virus worldwide. While antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition, individuals living with HIV remain at increased risk of various complications, including hematological abnormalities. Among these, splenic dysfunction has

garnered significant attention for its potential impact on disease progression and clinical outcomes. Howell-Jolly bodies (HJBs), observed as cytoplasmic remnants within erythrocytes, have emerged as potential biomarkers of splenic dysfunction in HIV-infected individuals. The spleen plays a crucial role in immune surveillance and hematopoiesis, filtering aged or abnormal erythrocytes from circulation and maintaining red blood cell homeostasis. Splenic dysfunction, characterized by impaired splenic clearance and immune function, can lead to the retention of abnormal erythrocytes containing HJBs in circulation. In HIV-infected individuals, splenic dysfunction may result from various factors, including direct viral effects, opportunistic infections, chronic inflammation, and ART-related complications, all of which contribute to hematological abnormalities and disease progression.[1-10]

The detection of HJBs on peripheral blood smears offers a non-invasive means of assessing splenic function and identifying HIV-associated splenic dysfunction. Morphologically, HJBs appear as small, round, basophilic inclusions within erythrocytes, typically visualized on Wright-Giemsa or Romanowsky-stained smears. While traditionally regarded as indicative of functional asplenia or splenic dysfunction, the presence of HJBs in HIV patients suggests underlying abnormalities in erythropoiesis and compromised splenic function, reflecting the complex interplay between viral pathogenesis, immune dysregulation, and hematological perturbations. The clinical significance of HJBs in HIV-infected individuals extends beyond their morphological features, encompassing their potential as prognostic markers for disease progression and clinical outcomes. HJBs may contribute to clinical manifestations such as anemia, fatigue, and increased healthcare utilization, highlighting their clinical relevance in HIV-infected individuals. Given the complex etiology of splenic dysfunction in HIV, optimizing diagnostic strategies for identifying HJBs and assessing splenic function is crucial for guiding therapeutic interventions and improving clinical outcomes. While the presence of HJBs on peripheral blood smears is suggestive of splenic dysfunction, it lacks specificity to HIV and may be observed in other conditions, including functional asplenia, splenectomy, and certain hematological disorders. Therefore, additional diagnostic modalities, such as imaging studies (e.g., ultrasound, computed tomography) or functional assays (e.g., splenic scintigraphy), may be required to confirm the diagnosis and assess the severity of splenic dysfunction in HIV-infected individuals.[11-20]

This review aims to evaluate the diagnostic accuracy of HJBs in identifying HIV-associated splenic dysfunction, examining their morphological features, clinical significance, and implications for disease management.

Morphological Features of Howell-Jolly Bodies

Howell-Jolly bodies (HJBs) are distinctive intracellular inclusions observed within erythrocytes, characterized by their small, round, basophilic appearance on peripheral blood smears stained with Wright-Giemsa or Romanowsky stains. Typically ranging from 1 to 3 micrometers in diameter, these structures represent remnants of nuclear material that should have been expelled during erythrocyte maturation in the bone marrow. However, their persistence within circulating erythrocytes suggests a failure of the normal process of nuclear extrusion, often attributed to impaired splenic function or erythropoiesis. Microscopically, Howell-Jolly bodies appear as

single, spherical structures located within the cytoplasm of erythrocytes, displaying uniform staining characteristics and well-defined borders. They are best visualized using a light microscope at high magnification, where they stand out as distinct, dark-staining inclusions against the background of erythrocyte cytoplasm. Despite their small size, Howell-Jolly bodies are readily identifiable by experienced hematopathologists and serve as important morphological indicators of underlying hematological abnormalities. In HIV-infected individuals, the presence of Howell-Jolly bodies may signify compromised splenic function, either due to direct viral effects on the spleen or secondary to chronic inflammation and immune dysregulation. While Howell-Jolly bodies are traditionally associated with functional asplenia or splenic dysfunction, their presence in HIV patients underscores the complex interplay between viral pathogenesis, hematological abnormalities, and immune perturbations. Therefore, the detection of Howell-Jolly bodies on peripheral blood smears holds diagnostic significance, offering valuable insights into splenic function and disease progression in HIV-infected individuals.[21-30]

Clinical Significance of Howell-Jolly Bodies

The clinical significance of Howell-Jolly bodies (HJBs) in HIV-infected individuals extends beyond their morphological appearance to encompass their potential as indicators of underlying hematological abnormalities and splenic dysfunction. While traditionally regarded as benign inclusions, the presence of HJBs in peripheral blood smears serves as a valuable diagnostic clue, particularly in the context of HIV-associated splenic dysfunction. The abundance of HJBs reflects compromised splenic clearance and immune function, providing clinicians with insights into disease severity and progression. In HIV-infected individuals, the presence of HJBs has been correlated with advanced stages of disease, including increased viral loads, decreased CD4+ T-cell counts, and heightened susceptibility to opportunistic infections. As such, HJBs may serve as prognostic markers for disease progression, guiding risk stratification and therapeutic interventions in affected individuals. Furthermore, the presence of HJBs may contribute to clinical manifestations such as anemia, fatigue, and increased healthcare utilization, further underscoring their clinical significance in HIV-infected patients. The detection of HJBs prompts closer monitoring and may influence therapeutic decisions in HIV patients, particularly those with splenic dysfunction. By recognizing the clinical significance of HJBs and integrating them into diagnostic algorithms, clinicians can optimize patient care and improve clinical outcomes in HIV-infected individuals. Additionally, longitudinal assessment of HJB abundance over time may serve as a dynamic marker of treatment response and disease progression, guiding adjustments to antiretroviral therapy (ART) and adjunctive therapies to optimize clinical outcomes in HIV-infected individuals.[31-40]

Diagnostic Accuracy of Howell-Jolly Bodies

The diagnostic accuracy of Howell-Jolly bodies (HJBs) in identifying HIV-associated splenic dysfunction remains a subject of debate, given the complexities of HIV infection and the multifactorial nature of splenic dysfunction. While the presence of HJBs on peripheral blood smears is suggestive of splenic dysfunction, it lacks specificity to HIV and may be observed in other conditions, including functional asplenia, splenectomy, and certain hematological disorders.

Therefore, reliance solely on the presence of HJBs for diagnosing splenic dysfunction in HIV-infected individuals may lead to false positives or misinterpretation of results. To enhance diagnostic accuracy, additional diagnostic modalities, such as imaging studies (e.g., ultrasound, computed tomography) or functional assays (e.g., splenic scintigraphy), may be required to confirm the diagnosis and assess the severity of splenic dysfunction in HIV-infected individuals. Imaging modalities offer the advantage of visualizing splenic morphology and assessing splenic size, while functional assays provide information on splenic function and clearance capacity. Combining these modalities with the detection of HJBs on peripheral blood smears may improve diagnostic accuracy and inform therapeutic interventions in HIV-infected individuals with suspected splenic dysfunction. By integrating multiple diagnostic modalities and biomarkers, clinicians can improve diagnostic accuracy and tailor therapeutic interventions to address splenic dysfunction in HIV-infected individuals, ultimately improving clinical outcomes and quality of life.[41-50]

Implications for Disease Management

The implications of Howell-Jolly bodies (HJBs) for disease management in HIV-infected individuals are multifaceted, encompassing diagnostic strategies, therapeutic interventions, and overall patient care. While the presence of HJBs serves as a valuable diagnostic clue for splenic dysfunction, clinicians must adopt a comprehensive approach to disease management that considers the complex interplay between viral pathogenesis, immune dysregulation, and hematological abnormalities in HIV-infected individuals. Optimizing diagnostic strategies for identifying splenic dysfunction in HIV-infected individuals is crucial for guiding therapeutic interventions and improving clinical outcomes. In addition to the detection of HJBs on peripheral blood smears, clinicians may employ imaging modalities (e.g., ultrasound, computed tomography) or functional assays (e.g., splenic scintigraphy) to confirm the diagnosis and assess the severity of splenic dysfunction. By integrating multiple diagnostic modalities and biomarkers, clinicians can improve diagnostic accuracy and tailor therapeutic interventions to address splenic dysfunction in HIV-infected individuals.[51-60]

Therapeutic interventions for HIV-infected individuals with splenic dysfunction aim to mitigate the adverse effects of compromised splenic function and enhance overall clinical outcomes. This may include optimizing antiretroviral therapy (ART) to suppress viral replication, restore immune function, and mitigate hematological complications. Additionally, adjunctive therapies targeting hematological abnormalities (e.g., erythropoiesis-stimulating agents, iron supplementation) or immune modulation (e.g., cytokine therapy, immune checkpoint inhibitors) may be considered to improve clinical outcomes and enhance quality of life in affected individuals. Comprehensive patient care for HIV-infected individuals with splenic dysfunction should also include psychosocial support, nutritional counseling, and adherence support to address the multifaceted impact of the disease on physical, psychological, and social well-being. By adopting a holistic approach to disease management, clinicians can optimize clinical outcomes, improve quality of life, and enhance overall patient care for HIV-infected individuals with splenic dysfunction. Further research is warranted to elucidate the efficacy and safety of therapeutic interventions

targeting splenic dysfunction in HIV-infected individuals, ultimately optimizing personalized approaches to care and improving patient outcomes.[61-71]

Conclusion

Howell-Jolly bodies (HJBs) serve as valuable biomarkers of splenic dysfunction in HIV-infected individuals, offering diagnostic clues and prognostic insights into disease management. While the presence of HJBs on peripheral blood smears suggests compromised splenic function, their diagnostic accuracy in identifying HIV-associated splenic dysfunction remains uncertain. Therefore, clinicians must adopt a comprehensive approach to disease management that integrates multiple diagnostic modalities and biomarkers to improve diagnostic accuracy and guide therapeutic interventions. The implications of HJBs for disease management in HIV-infected individuals extend beyond diagnostic considerations to encompass therapeutic interventions and overall patient care. Optimal disease management requires a multifaceted approach that addresses the complex interplay between viral pathogenesis, immune dysregulation, and hematological abnormalities. By optimizing diagnostic strategies and tailoring therapeutic interventions to address splenic dysfunction in HIV-infected individuals, clinicians can improve clinical outcomes, enhance quality of life, and ultimately improve patient care.

References

1. Meyer-Myklestad MH, Medhus AW, Lorvik KB, Seljeflot I, Hansen SH, Holm K, Stiksrud B, Trøseid M, Hov JR, Kvale D, Dyrhol-Riise AM. Human immunodeficiency virus–infected immunological nonresponders have colon-restricted gut mucosal immune dysfunction. The Journal of infectious diseases. 2022;225(4):661-674.
2. Henderson DK, Dembry L, Fishman NO, Grady C, Lundstrom T, Palmore TN, Sepkowitz KA, Weber DJ, Society for Healthcare Epidemiology of America. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infection Control & Hospital Epidemiology. 2010;31(3):203-232.
3. d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Lo Caputo S, Arlotti M, Magnani G, Pellizzer G, Maggiolo F. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clinical Infectious Diseases. 2009;49(4):612-622.
4. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (Nijpp). 2023;3(2):64-7.
5. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian J Dental Health Sci [Internet]. 2023 Jun. 15 [cited 2024 May 4];3(2):7-14. Available from: http://ajdhs.com/index.php/journal/article/view/39
6. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45

7. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
8. Obeagu EI, Obeagu GU (2024). Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024; 11(2): 9-19.
9. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
10. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
11. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
12. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
13. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
14. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
15. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
16. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
17. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
18. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
19. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916.

https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
20. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
21. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
22. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
23. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
24. Mehta AB, Hoffbrand AV. Haematology at a Glance. John Wiley & Sons; 2009.
25. Sadelov IO, Bobrynina V, Krasilnikova M, Smetanina N. 1Federal scientific clinical center of pediatric hematology, oncology and immunology named after Dmitriy Rogachev, Moscow, Russian Federation Background: Hemoglobinopathies are heterogeneous group of diseases caused by qualitative (abnormal Hb) or quantitative (thalassemia) failure in. In18TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION STOCKHOLM, SWEDEN JUNE 13-16, 2013 2008; 93(s1):699.
26. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
27. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
28. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005

29. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
30. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
31. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
32. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
33. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
34. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
35. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
36. Lutgendorf SK. Cognitive-behavioral stress management in a symptomatic HIV-1 seropositive population: Effects on mood, coping, immune and neuroendocrine factors. University of Miami; 1994.
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf

39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
41. Nikolouzakis TK, Falzone L, Lasithiotakis K, Krüger-Krasagakis S, Kalogeraki A, Sifaki M, Spandidos DA, Chrysos E, Tsatsakis A, Tsiaoussis J. Current and future trends in molecular biomarkers for diagnostic, prognostic, and predictive purposes in non-melanoma skin cancer. Journal of Clinical Medicine. 2020;9(9):2868.
42. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
43. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
44. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
45. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
46. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
47. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.

48. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
49. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
50. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
51. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
52. Obeagu EI. Erythropoietin in HIV: Bridging the Gap Between Hematology and Virology. Elite Journal of HIV. 2024;2(3):42-54.
53. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024 Jan 12;103(2):e36937.
54. Obeagu EI, Obeagu GU. GATA-1 Regulation of Erythroid Progenitor Cell Differentiation in HIV/AIDS: Molecular Insights and Therapeutic Implications. Elite Journal of Haematology, 2024; 2 (4).:141-59.
55. Reddy R. *Study of Hematological Profile in HIV Infected Patients* (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)). 2018.
56. Canny SP, Orozco SL, Thulin NK, Hamerman JA. Immune Mechanisms in Inflammatory Anemia. Annual review of immunology. 2023; 41:405-429.
57. Checconi P, De Angelis M, Marcocci ME, Fraternale A, Magnani M, Palamara AT, Nencioni L. Redox-modulating agents in the treatment of viral infections. International Journal of Molecular Sciences. 2020;21(11):4084.
58. Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and inflammation driven pathophysiology of iron homeostasis—mechanistic insights into anemia of inflammation and its treatment. Nutrients. 2021;13(11):3732.
59. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clinical Infectious Diseases. 2002;35(9):1127-1134.
60. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV. 2024;2(2):60-73.
61. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9):e37354.
62. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.

63. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
64. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
65. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review. 2024;2(1):17-41.
66. Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral research. 2010;85(1):25-33.
67. Channaveerappanavar PB. *Study of Immunological Recovery in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients on Second Line Anti Retroviral Drugs-A Prospective Study* (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)). 2017.
68. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Quiescence in HIV: Implications for Therapy. Elite Journal of Medicine. 2024;2(4):19-36.
69. Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology, 2024; 2(5):* 126-137
70. Obeagu. Howell-Jolly Bodies in Pediatric HIV: Clinical Considerations and Management Strategies. Elite Journal of Nursing and Health Science, 2024; 2(5):1-11
71. Obeagu EI. The Impact of Howell-Jolly Bodies on Quality of Life in HIV Patients: A Review. Elite Journal of Public Health, 2024; 2 (5): 32-42